KING PHARMACEUTICALS Company Top Insiders
| KG Stock | 22.92 0.18 0.78% |
KING PHARMACEUTICALS employs about 4 people. The company is managed by 4 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Examination of KING PHARMACEUTICALS's management performance can provide insight into the company performance.
KING PHARMACEUTICALS Management Team Effectiveness
The KING PHARMACEUTICALS's current Return On Tangible Assets is estimated to increase to 0.07. The KING PHARMACEUTICALS's current Return On Capital Employed is estimated to increase to 0.04. At this time, KING PHARMACEUTICALS's Fixed Asset Turnover is most likely to increase in the upcoming years. The KING PHARMACEUTICALS's current Return On Assets is estimated to increase to 0.07, while Other Assets are projected to decrease to roughly 228.2 M. KING PHARMACEUTICALS's management efficiency ratios could be used to measure how well KING PHARMACEUTICALS manages its routine affairs as well as how well it operates its assets and liabilities.KING PHARMACEUTICALS Quarterly Income Before Tax |
|
KING PHARMACEUTICALS Workforce Comparison
KING PHARMACEUTICALS INC is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 19,295. KING PHARMACEUTICALS adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
KING PHARMACEUTICALS Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific KING PHARMACEUTICALS insiders, such as employees or executives, is commonly permitted as long as it does not rely on KING PHARMACEUTICALS's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, KING PHARMACEUTICALS insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2011-03-01 | 0.2687 | 18 | 67 | 552,402 | 4,232,603 |
| 2010-12-01 | 0.4 | 6 | 15 | 414,760 | 754,586 |
| 2010-06-01 | 10.0 | 10 | 1 | 155,809 | 7,000 |
| 2010-03-01 | 1.0909 | 24 | 22 | 1,289,168 | 270,876 |
| 2009-12-01 | 0.875 | 7 | 8 | 220,834 | 226,367 |
| 2009-06-01 | 2.3333 | 7 | 3 | 107,506 | 14,935 |
| 2009-03-01 | 2.0 | 30 | 15 | 1,242,677 | 96,814 |
| 2008-12-01 | 0.875 | 7 | 8 | 170,440 | 171,440 |
| 2008-06-01 | 0.5 | 8 | 16 | 124,689 | 173,556 |
| 2007-03-01 | 3.0 | 27 | 9 | 475,555 | 53,925 |
| 2006-12-01 | 0.7 | 7 | 10 | 10,668 | 34,565 |
| 2006-03-01 | 2.8 | 14 | 5 | 202,380 | 23,260 |
| 2005-12-01 | 1.5 | 6 | 4 | 345,612 | 1,925 |
| 2005-06-01 | 7.0 | 7 | 1 | 70,000 | 0.00 |
| 2005-03-01 | 0.1667 | 1 | 6 | 424.00 | 119,800 |
| 2004-03-01 | 2.3333 | 7 | 3 | 670,030 | 1,248 |
| 2003-09-01 | 7.0 | 7 | 1 | 70,000 | 0.00 |
KING PHARMACEUTICALS Notable Stakeholders
A KING PHARMACEUTICALS stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as KING PHARMACEUTICALS often face trade-offs trying to please all of them. KING PHARMACEUTICALS's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting KING PHARMACEUTICALS's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Bradford Ledbetter | CEO Director | Profile | |
| Terry Ledbetter | Executive Chairman | Profile | |
| Patrick CPA | President CFO | Profile | |
| Lawrence JD | Chief Officer | Profile |
About KING PHARMACEUTICALS Management Performance
The success or failure of an entity such as KING PHARMACEUTICALS INC often depends on how effective the management is. KING PHARMACEUTICALS management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of KING management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the KING management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.07 | 0.07 | |
| Return On Capital Employed | 0.04 | 0.04 | |
| Return On Assets | 0.07 | 0.07 |
KING PHARMACEUTICALS Workforce Analysis
Traditionally, organizations such as KING PHARMACEUTICALS use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare KING PHARMACEUTICALS within its industry.KING PHARMACEUTICALS Manpower Efficiency
Return on KING PHARMACEUTICALS Manpower
| Revenue Per Employee | 1.3M | |
| Revenue Per Executive | 1.3M | |
| Net Income Per Employee | 81.1K | |
| Net Income Per Executive | 81.1K | |
| Working Capital Per Employee | 934.4K | |
| Working Capital Per Executive | 934.4K |
Complementary Tools for KING Stock analysis
When running KING PHARMACEUTICALS's price analysis, check to measure KING PHARMACEUTICALS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy KING PHARMACEUTICALS is operating at the current time. Most of KING PHARMACEUTICALS's value examination focuses on studying past and present price action to predict the probability of KING PHARMACEUTICALS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move KING PHARMACEUTICALS's price. Additionally, you may evaluate how the addition of KING PHARMACEUTICALS to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |